A DOUBLE-BLIND TRIAL OF LOW DOSES OF SUBCUTANEOUS HEPARIN IN THE PREVENTION OF DEEP-VEIN THROMBOSIS AFTER MYOCARDIAL INFARCTION*1

The Lancet ◽  
1973 ◽  
Vol 302 (7835) ◽  
pp. 934-936 ◽  
Author(s):  
C WARLOW
Keyword(s):  
Myocardial Infarction ◽  
Deep Vein Thrombosis ◽  
Low Doses ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Vein Thrombosis ◽  
Subcutaneous Heparin ◽  
Deep Vein

A Double-Blind Trial of Intramuscular Stanozolol in the Prevention of Postoperative Deep Vein Thrombosis Following Elective Abdominal Surgery

1984 ◽  
Vol 51 (01) ◽  
pp. 071-074 ◽  
Author(s):  
S L Blarney ◽  
B M McArdle ◽  
P Burns ◽  
D C Carter ◽  
G D O Lowe ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Placebo Group ◽  
Controlled Trial ◽  
Double Blind Trial ◽  
Double Blind ◽  
Vein Thrombosis ◽  
Postoperative Deep Vein Thrombosis ◽  
Deep Vein ◽  
To Receive

SummaryFibrinolytic shutdown may be important in the development of postoperative deep vein thrombosis (DVT). We have previously shown that stanozolol 50 mg, given intramuscularly 24 hr before surgery, prevents the decrease in plasminogen activator activity (PA) seen on the first postoperative day in patients at high risk of DVT. To investigate the role of fibrinolytic shutdown in causation of DVT, sixty patients were randomised in a double-blind controlled trial to receive stanozolol or placebo intramuscularly, and DVT was detected by leg scanning and confirmed by venography. Scan positive DVT occurred in IT of 31 placebo patients (35%) and 12 of 29 who received stanozolol (41%). A significant decrease in PA was confirmed in the placebo group, while stanozolol caused a significant increase in PA on the first postoperative day. Patients in either group who did not develop DVT showed minimal changes in PA. We conclude that prevention of fibrinolytic shutdown by this regimen of stanozolol does not prevent postoperative DVT, and that further studies are required to clarify the relationships of postoperative fibrinolysis and DVT.

LOW DOSES OF SUBCUTANEOUS HEPARIN IN THE PREVENTION OF DEEP VEIN THROMBOSIS AFTER GYNAECOLOGICAL SURGERY

1973 ◽  
Vol 80 (5) ◽  
pp. 469-472 ◽  
Author(s):  
R. M. Ballard ◽  
P. J. Bradley-Watson ◽  
F. D. Johnstone ◽  
A. Kenney ◽  
T. G. McCarthy ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Low Doses ◽  
Gynaecological Surgery ◽  
Vein Thrombosis ◽  
Subcutaneous Heparin ◽  
Deep Vein

Postoperative Deep Vein Thrombosis

1975 ◽  
Author(s):  
I. C. Gordon-Smith
Keyword(s):  
Deep Vein Thrombosis ◽  
Cumulative Effect ◽  
Controlled Study ◽  
Blood Levels ◽  
Double Blind ◽  
Vein Thrombosis ◽  
Postoperative Deep Vein Thrombosis ◽  
Subcutaneous Heparin ◽  
Heparin Administration ◽  
Deep Vein

Subcutaneous heparin therapy has been shown in several recent studies to be an effective agent in the prevention of postoperative deep vein thrombosis (DVT). However, DVT has not been abolished by such therapy and an increase in haemorrhagic complications, notably wound haematomata, has been reported after its use.In an ongoing double blind randomised controlled study the effects of heparin on DVT and postoperative complications have been correlated with blood heparin levels. Thus far some fifty patients have been studied with the following preliminary conclusions :(I) Subcutaneous heparin administration results in markedly variable blood levels,being maximal two hours after injection at between 0.01-0.30 I.U./ml. (II) 12-hourly injections of 5000 I.U. heparin did not have a cumulative effect over one week.(III) Of seven patients with blood heparin levels in excess of 0.2 I.U./ml, four developed a wound haematoma. Of seventeen patients with blood heparin levels of less than 0.2 I.U./ml only two patients developed this complication.(IV) Thus far 125I-Fibrinogen detected DVT has not occurred in the heparin treated patients.

Acute Deep Vein Thrombosis Treated with Porcine Plasmin

1974 ◽  
Vol 32 (02/03) ◽  
pp. 468-482 ◽  
Author(s):  
O Storm ◽  
P Ollendorff ◽  
E Drewsen ◽  
P Tang
Keyword(s):  
Deep Vein Thrombosis ◽  
Lower Limb ◽  
Initial Dose ◽  
Treated Group ◽  
Allergic Reactions ◽  
Double Blind ◽  
Vein Thrombosis ◽  
Thrombolytic Effect ◽  
Acute Deep Vein Thrombosis ◽  
Deep Vein

SummaryThe thrombolytic effect of pig plasmin was tested in a double blind trial on patients with deep venous thrombosis in the lower limb. Only patients with not more than three days old thrombi were selected for this study. The diagnosis of deep vein thrombosis was made clinically and confirmed by phlebography. Lysofibrin Novo (porcine plasmin) or placebo (porcine plasminogen) was administered intravenously to the patients. The enzyme and the placebo were delivered as lyophilized powder in labelled bottles - the contents of the bottles were unknown to the doctor in charge of the clinical administration of the trial. An initial dose of plasmin/plasminogen of 30 unit per kg body weight given slowly intravenously (1-1% hours infusion) was followed by a maintenance dosis of 15 per cent the initial dose per hour for the following 5-7 hours. In most cases a similar maintenance dosis was given the next day. In all patients heparin was administered after ending the plasmin/plasminogen infusion. The results of the treatment was evaluated clinically as well as by control phlebo- grams the following days.A statistically significant improvement was found in the plasmin treated group compared with the placebo (plasminogen) treated group. Thrombolysis was obtained clinically and phlebographically in 65 per cent of the plasmin treated group, but only in 15 per cent of the control patients were improvements found.This study has thus demonstrated that plasmin treatment according to a standard scheme was able to induce thrombolysis. There were only a few and insignificant side effects. Allergic reactions have not been seen and only very simple tests are required.

Low-dose subcutaneous heparin in prevention of deep-vein thrombosis

1972 ◽  
Vol 10 (23) ◽  
pp. 89-91
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Venous Thrombosis ◽  
Low Dose ◽  
Fatal Pulmonary Embolism ◽  
Vein Thrombosis ◽  
Subcutaneous Heparin ◽  
Prevention And Treatment ◽  
Deep Vein ◽  
Low Dosage

Earlier this year1 we discussed the prevention and treatment of venous thrombosis and concluded that heparin in low dosage seemed the most promising drug for preventing deep-vein thrombosis postoperatively, although the optimum regimen was not yet known. Sharnoff and his associates who began this work 10 years ago claim to have shown that this treatment largely prevents fatal pulmonary embolism.2

scholarly journals Heparin in the Prevention of Deep Vein Thrombosis after Myocardial Infarction

BMJ ◽  
1972 ◽  
Vol 2 (5811) ◽  
pp. 436-438 ◽  
Author(s):  
A. J. Handley ◽  
P. A. Emerson ◽  
P. R. Fleming
Keyword(s):  
Myocardial Infarction ◽  
Deep Vein Thrombosis ◽  
Vein Thrombosis ◽  
Deep Vein
Sign in / Sign up

Export Citation Format

Share Document